{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:07:00Z","timestamp":1790996820907,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ymthe.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T21:18:25Z","timestamp":1551820705000},"page":"878-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Frank","family":"DeRosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barak","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Heartlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.03.001_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease - current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genomics"},{"key":"10.1016\/j.ymthe.2019.03.001_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jgf2.76","article-title":"Fabry disease and its cardiac involvement","volume":"18","author":"Kubo","year":"2017","journal-title":"J.\u00a0Gen. Fam. Med."},{"key":"10.1016\/j.ymthe.2019.03.001_bib3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2019.03.001_bib4","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2174\/092986712800784739","article-title":"Novel gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study","volume":"19","author":"Auray-Blais","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymthe.2019.03.001_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.03.001_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/diseases5020015","article-title":"Biomarkers and Imaging Findings of Anderson-Fabry Disease-What We Know Now","volume":"5","author":"Beir\u00e3o","year":"2017","journal-title":"Diseases"},{"key":"10.1016\/j.ymthe.2019.03.001_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.pcad.2009.11.002","article-title":"Anderson-Fabry disease and the heart","volume":"52","author":"O\u2019Mahony","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.ymthe.2019.03.001_bib8","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2019.03.001_bib9","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/ki.2008.522","article-title":"Renal manifestations in Fabry disease and therapeutic options","volume":"74","author":"Torra","year":"2008","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ymthe.2019.03.001_bib10","first-page":"1","article-title":"Enzyme Replacement Therapy for Fabry Disease","volume":"4","author":"Sanchez-Nino","year":"2016","journal-title":"J.\u00a0Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymthe.2019.03.001_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.ymthe.2019.03.001_bib12","doi-asserted-by":"crossref","first-page":"e57631","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.03.001_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.03.001_bib14","first-page":"291","article-title":"Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease","volume":"1","author":"Pastores","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.ymthe.2019.03.001_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4155\/cli.14.35","article-title":"Agalsidase Alfa for the Treatment of Fabry Disease: A Closer Look","volume":"4","author":"Lipinski","year":"2014","journal-title":"Clin. Investig."},{"key":"10.1016\/j.ymthe.2019.03.001_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-200767030-00007","article-title":"Agalsidase Beta: a review of its use in the management of Fabry disease","volume":"67","author":"Keating","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2019.03.001_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/gim.2014.79","article-title":"Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?","volume":"17","author":"Pisani","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2019.03.001_bib18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2019.03.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/8904_2014_371","article-title":"Innate and Adaptive Immune Response in Fabry Disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2019.03.001_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/8904_2011_106","article-title":"Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2019.03.001_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/8904_2011_44","article-title":"Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience","volume":"3","author":"Ghali","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2019.03.001_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2019.03.001_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","article-title":"Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)","volume":"102","author":"Linthorst","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.03.001_bib24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.12089","article-title":"Fabry disease: is there a role for enzyme replacement therapy?","volume":"274","author":"Mehta","year":"2013","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ymthe.2019.03.001_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nbt0896-975","article-title":"Getting the glycosylation right: implications for the biotechnology industry","volume":"14","author":"Jenkins","year":"1996","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2019.03.001_bib26","first-page":"95","article-title":"Bioprocess factors affecting glycoprotein oligosaccharide structure","volume":"76","author":"Goochee","year":"1992","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.ymthe.2019.03.001_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2019.03.001_bib28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/mt.2012.7","article-title":"Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin","volume":"20","author":"Karik\u00f3","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.03.001_bib29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI65351","article-title":"Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism","volume":"123","author":"Mays","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2019.03.001_bib30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2019.03.001_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omtn.2017.04.006","article-title":"Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA","volume":"7","author":"Schrom","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2019.03.001_bib32","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1021\/acs.nanolett.5b03528","article-title":"An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in\u00a0Vivo","volume":"15","author":"Li","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2019.03.001_bib33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/mt.2012.250","article-title":"Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy","volume":"21","author":"Wang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.03.001_bib34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/gt.2016.46","article-title":"Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system","volume":"23","author":"DeRosa","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2019.03.001_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jconrel.2016.08.037","article-title":"Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration","volume":"239","author":"Badieyan","year":"2016","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2019.03.001_bib36","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2019.03.001_bib37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2019.03.001_bib38","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2019.03.001_bib39","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2019.03.001_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40348-015-0022-6","article-title":"Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies","volume":"2","author":"Antony","year":"2015","journal-title":"Mol. Cell Pediatr."},{"key":"10.1016\/j.ymthe.2019.03.001_bib41","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41467-018-06508-3","article-title":"Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection","volume":"9","author":"Tiwari","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2019.03.001_bib42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.22203\/eCM.v033a22","article-title":"Tendon healing induced by chemically modified mRNAs","volume":"33","author":"Groth","year":"2017","journal-title":"Eur. Cell. Mater."},{"key":"10.1016\/j.ymthe.2019.03.001_bib43","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ymthe.2018.01.006","article-title":"G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a","volume":"26","author":"Roseman","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.03.001_bib44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jgm.2748","article-title":"Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy","volume":"15","author":"Bangel-Ruland","year":"2013","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2019.03.001_bib45","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.03.001_bib46","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1080\/15476286.2018.1475178","article-title":"Arginase I mRNA therapy - a novel approach to rescue arginase 1 enzyme deficiency","volume":"15","author":"Asrani","year":"2018","journal-title":"RNA Biol."},{"key":"10.1016\/j.ymthe.2019.03.001_bib47","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2019.03.001_bib48","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2019.03.001_bib49","first-page":"8247935","article-title":"SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency","volume":"2018","author":"Connolly","year":"2018","journal-title":"J.\u00a0Nucleic Acids"},{"key":"10.1016\/j.ymthe.2019.03.001_bib50","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"136","author":"Houseley","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2019.03.001_bib51","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/clinchem\/48.10.1647","article-title":"Stability of endogenous and added RNA in blood specimens, serum, and plasma","volume":"48","author":"Tsui","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2019.03.001_bib52","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in\u00a0vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2019.03.001_bib53","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/adma.201505822","article-title":"Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In\u00a0Vivo mRNA Delivery","volume":"28","author":"Fenton","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2019.03.001_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2019.03.001_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/nnm.13.192","article-title":"Lipid-based nanoparticles in the systemic delivery of siRNA","volume":"9","author":"Lin","year":"2014","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.ymthe.2019.03.001_bib56","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.03.001_bib57","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.addr.2004.01.005","article-title":"Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor","volume":"56","author":"Zhao","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2019.03.001_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2007.11.002","article-title":"Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles","volume":"126","author":"Li","year":"2008","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2019.03.001_bib59","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2147\/IJN.S24447","article-title":"Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells","volume":"6","author":"Chen","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2019.03.001_bib60","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1038\/mtna.2013.22","article-title":"Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA","volume":"2","author":"McCaskill","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2019.03.001_bib61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","article-title":"Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects","volume":"63","author":"Maruyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2019.03.001_bib62","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in\u00a0vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.03.001_bib63","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.03.001_bib64","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1023\/A:1006915926732","article-title":"\u03b1-galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues","volume":"15","author":"Ishii","year":"1998","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ymthe.2019.03.001_bib65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.03.001_bib66","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/mp400584h","article-title":"Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform","volume":"11","author":"Xu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2019.03.001_bib67","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1099\/vir.0.80755-0","article-title":"Recognition of mRNA cap structures by viral and cellular proteins","volume":"86","author":"Fechter","year":"2005","journal-title":"J.\u00a0Gen. Virol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619300863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619300863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T02:47:36Z","timestamp":1606618056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619300863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1525001619300863"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}